Arvinas, Genentech, Roche deal

Arvinas granted Roche’s Genentech unit rights to develop new therapeutics using Arvinas’ protein degradation technology against multiple targets. Arvinas received an undisclosed upfront payment and is eligible for more than $300 million in milestones, plus tiered royalties. Genentech may opt to expand the deal to include more targets. ...